Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Florida Pedigree Enforcement For 30 “Specified” Drugs Begins Sept. 1

Executive Summary

Pfizer's cholesterol-lowering drug Lipitor could be one of the first additions to a list of 30 drugs with new "pedigree" paper requirements in Florida
Advertisement

Related Content

RFID Ready Or Not: State Laws And Industry Pilots Move e-Pedigree Forward
Drug Distributor Consolidation May Call For Change In Oversight, HDMA Says
FDA Anticounterfeiting Business Practices Seem To Be Met By NABP Rules
Reimportation Should Await Track/Trace Technology, HIGPA White Paper Says
FDA Counterfeit Task Force Continues Work On Wholesaler “Best Practices”
FDA Counterfeit Report Seeks “Electronic Pedigree” To Aid Drug Tracking
AARP Supports Canadian Imports To Place “Downward Pressure” On Rx Costs
FDA Counterfeiting Task Force To Look At Tighter Wholesaler Licensing
Pfizer Lipitor counterfeit crackdown
Wholesaler Arguments Against Rx Pedigree Papers “Weak” – Fla. Grand Jury
Advertisement
UsernamePublicRestriction

Register

PS042044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel